CCR4 and neoplasm: In conclusion, our data suggest that a combination of a CCR4-binding therapeutic that can block aTreg cell trafficking in tumors, tumor antigen immunization, and monoclonal antibodies may enhance the clinical efficacy of immunotherapies for HNSCC.